JP2025500522A5 - - Google Patents
Info
- Publication number
- JP2025500522A5 JP2025500522A5 JP2024538472A JP2024538472A JP2025500522A5 JP 2025500522 A5 JP2025500522 A5 JP 2025500522A5 JP 2024538472 A JP2024538472 A JP 2024538472A JP 2024538472 A JP2024538472 A JP 2024538472A JP 2025500522 A5 JP2025500522 A5 JP 2025500522A5
- Authority
- JP
- Japan
- Prior art keywords
- subfamily
- tcrαv
- binding moiety
- tcrα
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292859P | 2021-12-22 | 2021-12-22 | |
| US63/292,859 | 2021-12-22 | ||
| PCT/US2022/053705 WO2023122206A2 (en) | 2021-12-22 | 2022-12-21 | Multifuntional molecules binding to tcr and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500522A JP2025500522A (ja) | 2025-01-09 |
| JP2025500522A5 true JP2025500522A5 (https=) | 2026-01-16 |
Family
ID=86903607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538472A Pending JP2025500522A (ja) | 2021-12-22 | 2022-12-21 | Ｔｃｒに結合する多機能性分子およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240409636A1 (https=) |
| EP (1) | EP4453039A4 (https=) |
| JP (1) | JP2025500522A (https=) |
| KR (1) | KR20240161975A (https=) |
| CN (1) | CN118786150A (https=) |
| AU (1) | AU2022419371A1 (https=) |
| CA (1) | CA3242160A1 (https=) |
| GB (1) | GB2631849A (https=) |
| WO (1) | WO2023122206A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| EP4704897A1 (en) * | 2023-04-27 | 2026-03-11 | Marengo Therapeutics, Inc. | Combination therapies using molecules binding to tcr |
| WO2025049771A1 (en) * | 2023-08-30 | 2025-03-06 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
| WO2025147334A1 (en) * | 2024-01-05 | 2025-07-10 | Bright Biologics Llc | ANTI-c-MET/HER2 ANTIBODIES AND USES THEREOF |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001227966A1 (en) * | 2000-01-20 | 2001-07-31 | Chiron Corporation | Methods for treating tumors |
| WO2019035938A1 (en) * | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| AU2020416273A1 (en) * | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN115843312A (zh) * | 2020-04-24 | 2023-03-24 | 马伦戈治疗公司 | 结合至t细胞相关癌细胞的多功能性分子及其用途 |
-
2022
- 2022-12-21 AU AU2022419371A patent/AU2022419371A1/en active Pending
- 2022-12-21 CA CA3242160A patent/CA3242160A1/en active Pending
- 2022-12-21 JP JP2024538472A patent/JP2025500522A/ja active Pending
- 2022-12-21 CN CN202280092392.1A patent/CN118786150A/zh active Pending
- 2022-12-21 WO PCT/US2022/053705 patent/WO2023122206A2/en not_active Ceased
- 2022-12-21 KR KR1020247024329A patent/KR20240161975A/ko active Pending
- 2022-12-21 GB GB2409147.2A patent/GB2631849A/en active Pending
- 2022-12-21 EP EP22912450.8A patent/EP4453039A4/en active Pending
-
2024
- 2024-06-21 US US18/749,969 patent/US20240409636A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025500522A5 (https=) | ||
| GB2631849A (en) | Multifuntional molecules binding to TCR and uses thereof | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| JP7741732B2 (ja) | Ｂｃｍａを標的とする操作された免疫細胞及びその使用 | |
| JP2022088627A5 (https=) | ||
| US20200038443A1 (en) | Multi-function and multi-targeting car system and methods for use thereof | |
| JP2021530246A5 (https=) | ||
| US12570743B2 (en) | BCMA-targeting engineered immune cell and use thereof | |
| Kono et al. | Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer | |
| Wilkie et al. | Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling | |
| JP2021501570A5 (https=) | ||
| GB2623199A (en) | Multifunctional molecules binding to TCR and uses thereof | |
| Zhu et al. | Engineering high affinity humanized anti‐p185HER2/anti‐CD3 bispecific F (ab′) 2 for efficient lysis of p185HER2 overexpressing tumor cells | |
| JP2019512272A5 (https=) | ||
| JP2018064568A (ja) | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 | |
| GB2609554A (en) | Anti-TCR antibody molecules and uses thereof | |
| JP2017531687A5 (https=) | ||
| US20180028631A1 (en) | Anti-ssea4 chimeric antigen receptors and their use for treating cancer | |
| TWI797610B (zh) | 人源化cd19抗體及其應用 | |
| Abken et al. | Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity | |
| GB2641599A (en) | Multifunctional molecules binding to TCR and uses thereof | |
| Satta et al. | Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors | |
| Kulemzin et al. | Engineering chimeric antigen receptors | |
| JP2023522038A5 (https=) | ||
| JP2024546999A5 (https=) |